XML 25 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 14, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Registrant Name Coya Therapeutics, Inc.    
Entity Central Index Key 0001835022    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction Flag false    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 85,212,539
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Security12b Title Common Stock, par value $0.0001 per share    
Trading Symbol COYA    
Security Exchange Name NASDAQ    
Entity File Number 001-41583    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 85-4017781    
Entity Address Address Line1 5850 San Felipe St., Suite 500    
Entity Address City Or Town Houston    
Entity Address State Or Province TX    
Entity Address Postal Zip Code 77057    
City Area Code 800    
Local Phone Number 587-8170    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated By Reference

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant’s fiscal year ended December 31, 2024, are incorporated by reference in Part III of this Form 10-K.

    
Auditor Firm ID 410    
Auditor Name Weaver and Tidwell, L.L.P.    
Auditor Location Austin, Texas    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Coya Therapeutics, Inc. as of December 31, 2024 and 2023, and the related statements of operations, stockholders’ equity and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of Coya Therapeutics, Inc. as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

   
Entity Common Stock, Shares Outstanding   16,724,998